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Heparanase (Hpse) is the only known mammalian endo-β-D-glucuronidase that degrades
the glycosaminoglycan heparan sulfate (HS), found attached to the core proteins of heparan
sulfate proteoglycans (HSPGs). Hpse plays a homeostatic role in regulating the turnover
of cell-associated HS and also degrades extracellular HS in basement membranes (BMs)
and the extracellular matrix (ECM), where HSPGs function as a barrier to cell migration.
Secreted Hpse is harnessed by leukocytes to facilitate their migration from the blood to
sites of inflammation. In the non-obese diabetic (NOD) model of autoimmune Type 1 dia-
betes (T1D), Hpse is also used by insulitis leukocytes to solubilize the islet BM to enable
intra-islet entry of leukocytes and to degrade intracellular HS, an essential component for
the survival of insulin-producing islet beta cells. Treatment of pre-diabetic adult NOD mice
with the Hpse inhibitor PI-88 significantly reduced the incidence of T1D by ~50% and pre-
served islet HS. Hpse therefore acts as a novel immune effector mechanism in T1D. Our
studies have identified T1D as a Hpse-dependent disease and Hpse inhibitors as novel
therapeutics for preventingT1D progression and possibly the development ofT1D vascular
complications.
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INTRODUCTION
Heparanase (Hpse) is an endo-β-d-glucuronidase that degrades
the glycosaminoglycan heparan sulfate (HS). Cloning studies have
identified that catalytically active Hpse is encoded by a single
mammalian gene (1–3). Hpse is initially produced as an inactive
pre-proenzyme which undergoes post-translational processing to
yield a 65 kDa proenzyme for secretion. Proteolytic cleavage of
proheparanase by the cysteine protease cathepsin L leads to the
formation of catalytically active Hpse, a heterodimer consisting of
a 50 kDa (human) or 48 kDa (mouse) polypeptide non-covalently
bound to a 8 kDa peptide (1, 2, 4–8). HS is a linear polysaccharide
that consists of a repeating disaccharide composed of N -acetylated
glucosamine (GlcNAc) and uronic acid [glucuronic acid (GlcA) or
iduronic acid (IdoA)]. HS biosynthesis occurs in the Golgi com-
partment of cells, with the assembly of component sugar residues
occurring directly onto the core proteins of heparan sulfate pro-
teoglycans (HSPGs) (9–11). During the polymerization of HS
chains, selected sugar residues are chemically modified by a suite of
enzymes (N -deacetylase-N -sulfotranferase, C5 epimerase, and 2,
3, and 6-O-sulfotransferases), resulting in HS chains with regions
that are highly sulfated and other regions of lower or no sulfa-
tion (10, 11). The sulfated regions of HS, in particular, bind to a
vast array of bioactive ligands that include cytokines, chemokines,
growth factors, adhesion molecules, lipases, and proteases (12, 13).
Typically, HSPGs are localized at the cell surface (e.g., synde-
cans 1–4, glypicans 1–6), in the extracellular matrix (ECM), in
basement membranes (BMs) (e.g., perlecan, collagen type XVIII,
and agrin) and have been identified in the nucleus of certain
cells (14, 15). Secreted proheparanase rapidly interacts with cell
surface HSPGs and the proheparanase-HSPG complex subse-
quently undergoes endocytosis. Similarly, Hpse can be internalized
after binding to cell surface lipoprotein receptor-related proteins
(LPRs) and mannose-6-phosphate receptors (MPRs) (16). Inter-
nalized proheparanase is cleaved by intracellular cathepsin L at
acidic pH in late endosomes or lysosomes, to form catalytically
active Hpse which can either degrade co-endocytosed HS, thereby
regulating the turnover of cell-associated HS, or undergo storage
within the lysosomes for subsequent secretion (6, 17–21). Opti-
mal Hpse-mediated cleavage of glycosidic bonds in HS occurs at
pH 5.5–6.0 and typically at sites adjacent to N - or 6-O-sulfated
glucosamine (16, 22), e.g., the linkage of glucuronic acid to 6-
O-sulfated glucosamine (23). HS in BMs and ECM is degraded
by Hpse secreted by platelets, endothelial cells, leukocytes, and
metastasizing tumor cells (12). In these settings, Hpse activity can
result from (i) activation of proheparanase bound to cell surface
HSPG or to cation-independent MPRs (CIMPRs) by an extracel-
lular source of cathepsin L, e.g., produced by macrophages (24,
25); (ii) cytokine-, fatty acid-, or nucleotide-stimulated release of
an intracellular pool of catalytically active Hpse (26–29) which
may be subsequently captured by cell surface receptors such as
CIMPRs (25); or (iii) platelet degranulation (30). This regulated
release of Hpse in the local microenvironment limits the availabil-
ity of Hpse activity, preserving the essential and diverse biological
functions of HS.
Heparanase also exhibits non-enzymatic functions which
impact on cell signaling, adhesion, and migration, as well as on
gene expression. Such functions are generally expressed at neutral
pH (31–33). Interaction of Hpse with cell surface receptors on
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endothelial cells activates intracellular Akt, PI3K, and p38 kinase
signaling to stimulate cell migration and Src kinase-mediated
upregulation of vascular endothelial growth factor (VEGF) for
angiogenesis (6, 18, 34). Hpse lacking catalytic enzyme activity
has been shown to increase the expression of certain growth fac-
tors (35) and to facilitate cell binding to HS in the ECM and to
endothelial cells in vitro (32).
Intra-nuclear Hpse modulates intra-nuclear HS/HSPGs and
exerts direct effects on gene transcription. Transfer of Hpse to
the nucleus occurs via Hsp90 in endothelial cells following fatty
acid stimulation (29). Intra-nuclear Hpse decreases the level of the
HSPG syndecan-1 in the nucleus of myeloma cells (14) and cleaves
nuclear HS which in turn inhibits histone acetyltransferases (36).
Recently, active Hpse has been reported to directly mediate epi-
genetic effects by regulating histone methylation, a process that
directly influences the transcription of certain immune response
genes involved in T-cell migration and function, e.g., IL-2 and
IFN-γ (37). Hpse was also found to bind to the promoters of
micro-RNAs involved in T-cell differentiation (37) and to influ-
ence the transcription of genes encoding enzymes involved in
glucose metabolism (29). Such nuclear roles for Hpse, either with
or without HS-degrading activity, would be expected to impact on
T cells in inflammatory responses.
HEPARANASE AND INFLAMMATION
Heparan sulfate has several important biological functions which
are regulated by Hpse in inflammation. An inflammatory response
is generated when leukocytes are rapidly recruited from the blood
to sites of tissue injury. In the early stages of inflammation,
cell surface HS on cytokine-activated or inflamed endothelial
cells functions in presenting lymphocyte-attractant chemokines
to leukocytes in the vascular lumen (12, 38). The subsequent
immobilization of the leukocytes (e.g., T cells) at the endothe-
lial cell surface is enhanced by the binding of chemokine-activated
integrins on the leukocytes to adhesion molecules such as ICAM-
1 or VCAM-1 expressed on endothelial cells. Such interactions
could potentially be facilitated by the binding of T cell-bound
inactive Hpse to HS expressed on the surface of endothelial cells
(12, 32, 33). The chemokine-binding role for endothelial cell sur-
face HS may also function in establishing a chemokine gradient to
direct leukocyte migration across the endothelium (12). Having
crossed the blood vessel wall, most probably by passing between
endothelial cells, inflammatory leukocytes employ degradative
mechanisms to traverse the sub-endothelial BM. In fact BM HS,
particularly associated with the HSPG perlecan, helps the BM to
act as a barrier to leukocyte migration. This barrier property is
attributed to the length of HS chains (up to 400 sugar residues) and
to their intrinsic capacity to interact with other BM matrix pro-
teins, forming a cell-impenetrable scaffold (12). To overcome this
obstacle, leukocytes including T cells (39, 40), nearby endothelial
cells (26) and possibly platelets (40) produce Hpse to degrade BM
HS and proteases to destroy BM matrix proteins. The disassem-
bly of the BM matrix components aids the passage of leukocytes
across the BM and their entry into the surrounding tissue. Simi-
larly, Hpse is released by inflammatory leukocytes to solubilize HS
in the ECM of underlying tissues and to aid their navigation to
sites of inflammation (12). During the course of the degradation
of extracellular HS, HS-bound cytokines and chemokines can be
liberated into the local microenvironment, potentially augmenting
cell recruitment and exacerbating the inflammatory response (12).
The role for Hpse as a “path-maker” required by migrating
leukocytes is of particular significance for T cell-mediated autoim-
mune diseases. Indeed, Hpse activity represents a prime target for
anti-inflammatory drug development. Experimental autoimmune
encephalitis (EAE; an experimental model of multiple sclerosis)
in rats was largely prevented by in vivo treatment with sulfated
polysaccharides. This effect was attributed to the inhibition of
Hpse produced by activated T cells, which in turn blocked the
solubilization of the sub-endothelial BM (41, 42). In a delayed-
type hypersensitivity (DTH) experimental model of inflamma-
tion, inhibition of endothelial cell-derived Hpse prevented the
degradation of sub-endothelial BM HS and leukocyte migration
(27). Hpse, possibly produced by inflammatory cells in rheuma-
toid arthritis in humans, may release cytokines and/or chemokines
from degraded HS in the ECM of rheumatoid joints, promoting
joint destruction (43). In ulcerative colitis and Crohn’s disease,
which represent chronic inflammatory disorders, Hpse is prefer-
entially produced by inflamed gut epithelial cells to drive a local
circuit of inflammation (24, 44). A role for Hpse has therefore
been established in a broad range of inflammatory conditions.
HEPARANASE AND THE PATHOGENESIS OF TYPE 1
DIABETES
Type 1 diabetes is an autoimmune disease which has been exten-
sively studied in non-obese diabetic (NOD) mice, a recognized
preclinical model of T1D in humans. During T1D, the insulin-
producing beta cells in the islets of Langerhans in the pancreas are
selectively destroyed by a T cell-mediated autoimmune response
(45). The priming of autoreactive T cells to their cognate beta
cell-specific autoantigens most probably occurs in the draining
pancreatic lymph nodes, possibly as a consequence of both the
abnormal responsiveness of effector T cells and inadequate con-
trol by regulatory T cells (46). Histological studies of NOD female
mice at an early age (~6–7 weeks) revealed that leukocytes ini-
tially accumulate around the periphery of the islets, forming
foci of non-destructive inflammation (insulitis). In adult pre-
diabetic mice, the insulitis advances to a destructive phenotype,
with peri-islet inflammatory leukocytes invading the islet cell mass
(45). However, this pathology does not occur as a synchronized
process throughout the pancreas, and the proportion of affected
islets as well as the severity of leukocyte invasion progressively
increases with time. Clinical symptoms of T1D are observed in
60–80% of female NOD mice from ~100 days of age or older, and
are characterized by blood glucose levels exceeding >20 mmol/L
(hyperglycemia).
In view of the established role for Hpse in leukocyte migration
in other experimental models of inflammation (see above), we
predicted that during T1D development, Hpse produced by islet
beta cell-specific autoreactive T cells, inflammatory leukocytes,
and possibly endothelial cells in the pancreatic vasculature, would
be required to degrade HS in the sub-vascular endothelial BM.
Thereafter, Hpse-mediated degradation of HS in the underlying
pancreatic ECM would allow the inflammatory cells to migrate
to individual islets and destroy the islet beta cells. Since T1D
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development is a chronic disease process, we furthermore spec-
ulated that there would be an on-going need for this degradative
activity. Our studies identified, however, that the requirement for
Hpse extended far beyond the enzymatic activity necessary for
leukocyte migration and the establishment of chronic inflamma-
tion. Indeed we discovered a critical role for Hpse at the level of the
islets themselves. This local involvement of Hpse stemmed from
the exceptionally high levels of HS normally associated with the
islets in situ (8). Initially we confirmed the presence of a BM at
the islet periphery (i.e., peri-islet BM) and revealed the HSPG per-
lecan as a previously unrecognized constituent (47). This HS+ve
islet BM was predicted to act as a barrier to invading cells, anal-
ogous to the sub-endothelial BM. On further investigation of the
distribution of HS in normal mouse islets in situ, we found that
HS was expressed not only in the islet BM but at extraordinarily
high levels throughout the islet cell mass (8). Immunohistochemi-
cal studies demonstrated that insulitis mononuclear cells (MNCs)
in NOD mice strongly expressed cell surface Hpse (Figure 1;
Figure 2, Stage 1). Furthermore, Western blotting analyses showed
that the insulitis leukocytes expressed high levels of catalytically
active Hpse at the time of diabetes onset in NOD mice, in con-
trast to the expression of inactive Hpse by peri-islet leukocytes
in young pre-diabetic mice (8). Intra-islet infiltration by insulitis
MNCs correlated with disruption of the islet BM (Figure 2, Stage
2), loss of the islet BM matrix proteins including the HSPG per-
lecan (47), progressive loss of intra-islet HS (Figure 2, Stage 3) and
beta cell death (Figure 2, Stage 4) (8). Our studies have strongly
indicated that such processes are mediated by catalytically active
Hpse (Figure 2, Stages 2–4). This newly unveiled role for Hpse has
more recently been validated using a transgenic mouse model of
acute T1D and adoptively transferred Hpse-knockout effector T
cells (unpublished data).
In vitro studies of beta cells isolated from normal mouse islets
revealed both the unique intracellular localization of HS and its
function in maintaining the viability of beta cells (8). Loss of
intracellular HS correlated with beta cell death and conversely, the
restoration of intracellular HS after culture of the beta cells with
HS mimetics, correlated with beta cell survival. HS replacement
not only preserved beta cell viability but rendered the beta cells
resistant to oxidative damage induced by treatment with hydrogen
peroxide [a source of reactive oxygen species (ROS)] (8). Col-
lectively these findings led us to speculate that the intrinsic role
of intracellular beta cell HS in situ in the pancreas is to protect
the beta cells from the physiological levels of ROS generated as a
consequence of their high metabolic and biosynthetic activity (8).
Furthermore, we reasoned that such a mechanism could compen-
sate for the low levels of free radical scavenger enzymes in beta
cells (48).
Together, our in vivo and in vitro studies identified multiple
roles for Hpse in T1D, namely promoting the migration of leuko-
cytes from pancreatic blood vessels (i.e., across the sub-endothelial
BM and through the pancreatic ECM), aiding the passage of leuko-
cytes across the islet BM and depleting islet beta cells of the intra-
cellular HS needed for their survival (Figure 2). In support of this
new paradigm, in vivo treatment of pre-diabetic adult NOD female
mice with the Hpse inhibitor/HS mimetic, PI-88, for 180 days sig-
nificantly delayed T1D onset and reduced the incidence of diabetes
FIGURE 1 | AutoimmuneT1D in NOD/Lt mice is characterized by cell
surface expression of heparanase on insulitis leukocytes. Histology
(A) and immunohistochemistry (B) of a pancreatic islet in a NOD/Lt female
mouse at the time of T1D onset shows islet infiltration by destructive
heparanase (Hpse)-expressing insulitis leukocytes (B) localized particularly
at the insulitis-islet interface, a process which leads to loss of beta cell HS
and beta cell death. (A) hematoxylin and eosin; (B) HP130 anti-heparanase
mAb. Ins, insulitis mononuclear cells; DI, damaged islet tissue; Hpse,
heparanase.
by ~50% (8). Compared to saline-treated control NOD mice, PI-
88 treatment significantly increased the proportion of pancreatic
islets that were intact, significantly reduced the proportion of islets
that showed destructive insulitis and better preserved the HS con-
tent of the islets (8). This hallmark study has therefore unveiled
T1D disease to be largely Hpse-dependent. The extraordinarily
high HS content of the beta cells, which is essential for their
survival, renders them particularly vulnerable to Hpse-mediated
damage. The localization of HS in the islet BM, which by con-
vention acts as a barrier to impede leukocyte infiltration, has also
been confirmed in normal human islets (49). Our studies suggest
that intracellular HS maintains beta cell survival at least in part,
by acting as a “free radical sink,” protecting the beta cells against
harmful chemical species generated endogenously. Our findings,
which we have subsequently validated in in vitro studies of human
islets and beta cells (unpublished data), therefore highlight Hpse
inhibitors as a new class of therapeutic that can potentially be used
to prevent T1D progression in humans.
HEPARANASE AND DIABETIC COMPLICATIONS
The current treatment for T1D is exogenous insulin therapy. While
insulin therapy keeps diabetic individuals reasonably healthy, pre-
cise control of blood glucose levels invariably fails to be achieved.
As a consequence, macrovascular and microvascular diseases
develop, resulting in heart disease, nephropathy, retinopathy, and
neuropathy. There is compelling evidence that diabetic vascular
complications are associated with the accumulation of advanced
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FIGURE 2 | Diagram showing a pancreatic islet and four stages ofT1D
disease driven by heparanase and loss of intra-islet HS. HS (intense
blue color) is shown in normal beta cells and in intact peri-islet BM. In
Stage 1 of the disease process, non-destructive insulitis mononuclear cells
produce heparanase (red dots). Onset of destructive insulitis occurs when
heparanase becomes catalytically active and degrades HS in the islet BM
(Stage 2). Damage to the islet BM barrier allows activated autoreactive T
cells to enter the islet cell mass where the local production of heparanase
leads to degradation of intracellular HS in islet beta cells (paling blue color;
Stage 3). Progression of HS depletion throughout the islet beta cell
population results in increased beta cell death (palest blue color in
“shriveled” beta cells; Stage 4), loss of insulin production and ultimately
the development of T1D. MNC, mononuclear cell; BM, basement
membrane; Hpse, heparanase.
glycation end products (AGEs) (50). Recent studies have also sug-
gested an important role for Hpse in the development of diabetic
nephropathy, a complication pertinent to both Type 1 and Type
2 diabetes. Underpinning this role, involvement of Hpse in pro-
teinuric renal disease has also been established in experimental
models of Adriamycin-induced nephropathy and passive Hey-
mann nephritis (22, 51, 52). Diabetic nephropathy is characterized
by an increase in the permeability of the glomerular BM (GBM),
leading to proteinuria, as well as by tubular and interstitial fibro-
sis (22, 53). Hyperglycemia has been reported to regulate and,
in fact, increase Hpse expression in renal epithelial cells in vitro
(54). This finding is consistent with the increased expression of
Hpse in renal glomeruli (e.g., glomerular podocytes) in human
diabetic nephropathy, with significant increased levels of Hpse in
the urine of diabetic patients and with a selective decrease in the
expression of GBM HS (55–58). Nephropathy resulting from long-
term streptozotocin-induced T1D was demonstrated in wildtype
mice but not in Hpse-knockout mice (59), supporting a role for
Hpse in this condition. The mechanism by which Hpse potenti-
ates diabetic proteinuria may involve altered interactions between
glomerular cells and HS-depleted GBM, the release of bioactive
molecules from degraded HS, or intracellular signaling in the
glomerular cells (22). Hpse is also strongly expressed in renal
tubules in diabetic nephropathy and may contribute to tubular
fibrosis via effects on FGF-2-signaling (53, 54, 58). An essential
role for Hpse in modulating renal tubular morphology was con-
firmed in diabetic Hpse-knockout mice, which unlike diabetic
wildtype controls, were free of histological evidence of tubular
fibrosis (59). In vitro studies have implicated albumin overload
and AGEs, rather than high glucose, in stimulating Hpse expres-
sion via the PI3K/Akt pathway in tubular endothelial cells, and in
the subsequent loss of cell surface HS (60). Inhibition of both Hpse
activity and the expression of tubular fibrosis markers in vitro by
sulodexide furthermore highlights Hpse as a potential therapeutic
target for preventing diabetic renal complications (53, 56).
Heparanase may also play a role in diabetic retinopathy.
Increased Hpse expression has been demonstrated in high glucose-
treated human retinal endothelial cells and in the retinal vascular
endothelium of streptozotocin-induced diabetic rats. In vitro,
increased levels of active Hpse correlated with enhanced levels
of VEGF, a critical angiogenic growth factor required for neo-
vascularization. Upregulation of VEGF in retinal endothelial cells
Frontiers in Immunology | Inflammation December 2013 | Volume 4 | Article 471 | 4
Simeonovic et al. Heparanase and type 1 diabetes
in vitro and in the retina of diabetic rats was inhibited by PI-88,
supporting a regulatory role for Hpse, possibly by Src activation
(61). At the level of leukocyte adhesion to rat retinal endothelium,
an early marker of diabetic retinopathy, Hpse inhibition correlated
with the decreased expression of the adhesion molecule ICAM-1
as well as VEGF, properties that implicate Hpse in both the arrest
of leukocytes in the retinal vasculature and the associated local vas-
cular dysfunction (62). Parallel studies have further demonstrated
a more general role for Hpse in high glucose-induced vascular
injury and have provided suggestive evidence for a role for Hpse
in the pathogenesis of diabetic atherosclerosis (63–65).
CONCLUDING REMARKS
The surprising contribution of Hpse to the pathogenesis of T1D
in NOD mice, together with the reported involvement of Hpse
in the development of vascular complications of diabetes, high-
light the potential application of safe and effective Hpse inhibitors
for T1D rescue and treatment. Our studies strongly suggest that
therapeutic intervention with dual activity Hpse inhibitors/HS
mimetics at early stages of the disease could not only prevent
the progression of T1D but potentially also fortify the HS content
of any remaining beta cells. By preserving the viability and func-
tion of residual insulin-producing beta cells, physiological control
of glycemia could be maintained without the need for exogenous
insulin therapy. Additional benefits of this therapeutic approach
would likely extend to preventing the secondary vascular com-
plications of diabetes. Moreover, the studies reviewed here also
support the potential treatment of established T1D with Hpse
inhibitors to arrest the progression of diabetic vascular diseases,
including nephropathy and retinopathy.
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